Skip to main content


Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Fig. 3

AADvac1-induced antibodies label tau extracts from corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) brains. Left: Patient R17, pre-treatment serum. Right: Serum of the same patient after six doses of AADvac1. The serum labels both high-molecular-weight aggregates and low-molecular-weight fragments of tau protein. Staining of Alzheimer’s disease (AD) brain extract is shown as a positive control

Back to article page